- About the Department
- Information for prospective students
- Information for industry
- Information for teachers
- Information for alumni
- MSc Programmes
- PhD/EngD Research Programmes
- Undergraduate (BEng/MEng) Courses
Professor of Regenerative Medicine Bioprocessing
Year 4 Tutor MEng Biochemical Engineering
Phone: +44 (0)20 7679 0140
Fax: +44 (0)20 7209 0703
PhD Biochemical Engineering, University College London (2004)
MB BS United Medical and Dental Schools of Guy’s and St. Thomas’s Hospitals (1994)
BSc (Hons) Clinical Sciences (Molecular Biology) Imperial College London, St. Mary’s Hospital Medical School and The Royal Postgraduate Medical School, Hammersmith (1993)
Professional Appointments, Honours and Awards
GMC registered medical practitioner
Fellow of the Royal College of Surgeons of England (FRCS)
Fellow of the Royal College of Surgeons in Ireland (FRCSI)
Fellow of Royal Society of Medicine plus Member of Council of the Medical Genetics Section
Member of the Royal Institution of Great Britain
Medical Research Council Clinical Research Fellow (October 1999 - August 2002)
Overall Winner - Medical Futures Innovation Awards, Medical Futures Innovation Awards. Award sponsor: NESTA (2002)
Winner - Best Biotech Start-Up Innovation Award, Medical Futures Innovation Awards, Award sponsor: Accenture (2002)
Stem Cell Clinical Liaison Committee Member, MRC (2003 to present)
Measurement Advisory Committee Working Group - The Measurement for Emerging Technologies (MET) Programme (a National Measurement System [NMS] Programme) (January 2004 - June 2007)
Cofounder with Dr. Stephen Minger (King’s College London), London Regenerative Medicine Network (May 2005 - present)
Cofounder and Senior Editor, “Regenerative Medicine” journal (October 2005 - present)
Oral and written evidence to the UK Stem Cell Initiative (UKSCI) chaired by Sir John Pattison (December 2005)
Steering Committee Member DTI/British Standards Institute (BSi) - PAS 83 - “Guidance on standards, standardised methods and regulation for cell-based therapeutics, from basic research to clinical application” (March 2005 - November 2006)
Editorial Board, “Nanomedicine” journal (August 2006 - present)
Editorial Advisory Board, “Medical Device Technology” journal (May 2006 - present)
Advisory Panel, University of Nottingham - MSc Stem Cell Technology Course - (September 2006 - present)
Winner of “ Outstanding Contribution to London Biotechnology” - London Biotechnology Network (2006) - Award shared with Dr. Stephen Minger (King’s College London)
Committee Member, Engineering & Biological Systems (EBS), BBSRC (October 2006 - present)
Steering Committee Member, UK National Stem Cell Network (UKNSCN) (December 2006 - present)
Royal Institution of Great Britain, Friday Evening Discourse, “Therapeutic potential of human stem cells: promise and pitfalls” (February 2007)
Advisor, Canadian National Stem Cell Network (2007)
Editorial Board, “Tissue Engineering” journal (January 2007 - present)
Scientific Advisory Board, Blond McIndoe Research Foundation (October 2007 - present)
The Hunterian Lecture, “Stem cells and tissue engineering - Hope or hype?“, Hunterian Society, London (November 2007)
Chair of Management Committee, Regenerative Medicine EPSRC Life Science Doctoral Training Centre - Collaboration between the universities of Loughborough, Keele and Nottingham (2007 – present)
Mason coordinates the Department’s activities in the emerging field of stem cell and regenerative medicine bioprocessing (RegenMed) which involves the majority of the Department’s staff including; Prof. Mike Hoare, Prof. Peter Dunnill, Prof. Gary Lye, Prof. Nigel Titchener-Hooker, Dr. Farlan Veraitch, Dr. Frank Baganz, Dr. Martina Micheletti, Dr Yuhong Zhou and Dr. Nicolas Szita. Together with a large and growing collection of external of collaborators from both academia and the regen industry, this multidisciplinary group is advancing the translation of the basic stem cell science into safe, clinically effective and affordable therapies for deployment in routine clinical practice.
RegenMed research is focused exclusively on the bioengineering aspects of stem cell and regenerative medicine translation including scale-up and scale-out. Taking a whole bioprocessing approach, i.e. the complete process from donor or patient all the way through to clinical implantation into the patient, requires the establishment of a number of collaborative partnerships with leading representatives of all the key stake holders groups (scientists, engineers, clinicians and regen companies) including:
- Prof. Peter Braude (King’s College London) – Human embryonic stem cell derivation under Good Manufacturing Conditions (GMP). Together with Emma Stephenson (UCL), Braude and Mason, are at the forefront of establishing international consensus standards for human embryonic stem cell derivation.
- Dr. Stephen Minger (King’s College London), Dr. Farlan Veraitch and Martin Town – Human embryonic stem cell expansion and harvesting methodologies.
- Prof. Gary Lye, Dr. Farlan Veraitch and Stem Cell Sciences plc together with Prof. Austin Smith (University of Cambridge) as a consultant – Automation of embryonic stem cell expansion and differentiation.
- Dr. Glyn Stacey and Dr. Lyn Healy (UK Stem Cell Bank, NIBSC) – A number of projects involving the expansion and controlled differentiation of stem cells to neurones including electrophysiological studies with Prof. Steven Bolsover (Dept. of Physiology, UCL) and scale-down bioreactor design with Linkam Scientific Ltd. and Martin Town.
- Prof. Nigel Titchener-Hooker, Dr. Roland Fleck (NIBSC), Dr. Yen Choo (Plasticell Ltd.) and Ludmila Ruban – The automation of “Combinatorial Cell Culture”, a novel platform technology designed to efficiently discover bioactive compounds involved in stem cell differentiation that could be used to precisely direct differentiation.
- Prof. Peter Andrews and Prof. Harry Moore (University of Sheffield/Axordia Ltd.) – An engineering approach to reprogramming human fibroblasts into “embryonic stem cell-like cells” using a novel gene therapy methodology.
- Prof. Mike Horton and Dr. Andrew Pelling (London Centre for Nanotechnology) and Dr. Farlan Veraitch – Atomic force microscopy applied to stem cell biology for better understanding the effects of bioprocessing on stem cells.
- Prof. Dame Julia Polak, Dr. Anne Bishop and Dr. Helen Rippon (Imperial College London) - Defined cell growth media to optimise stem cell differentiation into respiratory cells.
- Dr. Julie Daniels who directs the Cells for Sight Transplantation & Research Programme at Moorfields Eye Hospital and and Prof. Gabriel Aeppli (London Centre for Nanotechnology) - Characterisation and optimisation of the culture of limbal epithelial stem cells for clinical use.
- Prof. Mike Hoare, Dr. Stephen Ward (Onyvax Ltd.) and Dr. Julian Braybrook (LGC Ltd.) – Impact of the bioprocessing environment on the manufacturing scale-up of whole cell cancer vaccines.
- Prof. Pete Coffey (UCL Institute of Opthalmology). Director of The London Project to Cure Blindness - Bioprocessing of stem cells for the routine treatment of age-related macular degeneration.
Funding for the above research comes from the BBSRC, EPSRC, MRC, TSB Technology Programme and a Wolfson/Royal Society Laboratory Refurbishment Grant plus a wide range of company collaborators and charitable trusts.
Other recent research related activities include:
- Mission leader of the DTI funded Global Watch Mission, “Advanced Cell & Tissue Therapies - A mission to the US ” in September 2006. The purpose of the mission was to report on the advances being made in the USA with respect to the translation and commercialisation of stem cell and regenerative medicine technologies. Editor of the official mission report published in January 2007.
- Scientific Advisor to “Future Mix” a Wellcome Trust funded project being undertaken by Central Saint Martins College of Art and Design (Dr. Caterina Albano) and London School of Economics (Prof. Sarah Franklin) in collaboration with South Camden Community School (Ty Miller) and the Royal Institution which is looking at crossing the boundaries of art and science with respect to stem cells, cloning and regenerative medicine (February 2007-August 2008).
- Member of Steering Group and Member of the Committee Drafting Scheme (CDS) Steering Group, DIUS/British Standards Institute (BSi) PAS 84 - “Terms and Definitions used within Regenerative Medicine” (March 2007 to present)
- Working Group Member, Metrology Innovation R&D Programme, DIUS funded programme (replaced the earlier MET Programme) advises and peer reviews LGC, NEL and NPL with respect to the development of a measurement infrastructure for emerging technologies key to UK innovation and productivity (July 2007 to present)
- Member of the Oversight Group, Public dialogue project on the science and social and ethical issues of stem cell research – BBSRC and MRC are developing a public dialogue project around the science and social and ethical issues of human stem cell research, with funding from DIUS Sciencewise Programme (July 2007 to present)
Teaching and Training Activities
Within the Department, Mason has taken the lead role on the provision of stem cell and regenerative medicine bioprocessing teaching at all levels i.e. undergraduate, masters, postdoc and industry. Thus providing the essential teaching base for skilled bioprocessing engineers underpinning the regen industry.
Part of Mason’s teaching contribution is to direct all the stem cell and regenerative medicine bioprocessing aspects of the fourth year MEng programme including two courses. The first MEng course unit introduces students to advanced biochemical engineering and bioprocessing skills and in particular the ability to take fundamental stem cell science concepts and identify how best to translate them into real clinical outcomes. This allows students with engineering design skills to address an activity that will need novel approaches if robust, cost effective and safe cell therapies are to be available. Likewise, Mason has also established an MEng course unit which introduces the students to the latest basic science behind the next generation of regenerative medicine therapies with a view to their potential impact and challenges for biochemical engineering.
Together with Dr. Karen Smith and Dr. Farlan Veraitch, a new MBI module, “Stem Cells and Regenerative Medicine Bioprocessing” has been established. This course focuses on all aspects of whole bioprocessing including both universal (allogeneic) and patient specific (autologous) cell therapies plus tissue engineering and is taught by a team of internationally recognised industry experts. In addition, important related topics such as regulation and ethics from the commercial perspective are also covered.
A Masters level enterprise course for the Department’s full time MSc and doctoral students has been established in collaboration with Dr. Eli Keshavarz-Moore and Dr. Bill Hornby. Focusing on real case studies from the world of stem cells and regenerative medicine, the MSc and doctoral students, through a number of workshops and other activities, prepare in-depth business plans and presentations.
Mason also contributes to a first year undergraduate course aimed at encouraging students to realise the great value of biochemical engineering and its role in healthcare and society.
A major organisational requirement of the Department’s teaching and tutoring activities is to enable engineering students to acquire life science expertise. The Department strongly believes that this is best achieved by integrating the students with life scientists on their specialist courses and then providing the tutorial linkage to help guide the students. Mason heads up the departmental review group which meets with life science colleagues to oversee how best to address this rapidly developing area.
Mason is responsible for developing the stem cell and regenerative medicine bioprocessing activity of the EPSRC Engineering Doctorate (EngD) in Bioprocess Leadership Programme which is overall directed by Prof. Nigel Titchener-Hooker. Cell therapy and regenerative medicine companies/organisations which have already signed up to the scheme include; Axordia, Linkam Scientific, NIBSC, Moorfields Eye Hospital, Onyvax, Plasticell, Smith & Nephew, The Automation Partnership and the UK Stem Cell Bank.
*If you would like further information on any of these publications or news of related research, please contact email@example.com
Mason, C., Dunnill, P. 2008. A brief definition of Regenerative Medicine. Regen Med. 3(1), 1-5. doi:10.2217/174607126.96.36.199
Veraitch, F.S., Scott, R., Wong, J.W., Lye, G.J., Mason, C. The impact of manual processing on the expansion and directed differentiation of embryonic stem cells. Biotech Bioeng. In press/Advanced online publication. doi:10.1002/bit.21673
Mason, C., Dunnill, P. 2007. Lessons from the nascent regenerative medicine industry from the biotech sector. Regen Med. 2(5), 753-756. doi:10.2217/174607188.8.131.523
Mason, C., Hoare, M. 2007. Regenerative medicine bioprocessing: Building a conceptual framework based on early studies. Tissue Eng. 13(2), 301-311. doi:10.1089/ten.2006.0177
Mason, C. 2007. Regenerative Medicine 2.0. Regen Med. 2(1), 11-18. doi:10.2217/174607184.108.40.206
Pelling, A.E., Veraitch, F.S., Chu , C., Nicholls, B.M., Hemsley, A.L., Mason, C., Horton, M.A. 2007. Mapping of correlated cell membrane pulsations and fluctuations in human cells. Journal of Molecular Recognition. 20, 1-9. doi:10.1002/jmr.832
Stephenson, E.L., Braude, P.B., Mason, C., 2007. International community consensus standard for reporting derivation of human embryonic stem cell lines. Regen Med. 2(4), 349-362. doi:10.2217/174607220.127.116.119
Mason, C., Dunnill, P. 2007. Translational regenerative medicine research: Essential to discovery and outcome. Regen Med. 2(3), 227-229. doi:10.2217/17460718.104.22.168
Daniels, J.T., Harris, A.R., Mason, C. 2006. Corneal epithelial stem cells in health and disease. Stem Cell Reviews. 2(3), 247-254. ISSN:1550-8943
Markusen, J.F., Mason, C., Hull , D.A., Town, M.A., Tabor, A.B., Clements, M., Boshoff, C.H., Dunnill, P. 2006. Behaviour of adult human mesenchymal stem cells entrapped in alginate-GRGDY beads. Tissue Engineering. 12(4), 821-830. doi:10.1089/ten.2006.12.821
Mason, C., Hoare, M. 2006. Regenerative medicine bioprocessing: The need to learn from the experience of other fields. Regen Med. 1(5), 615-623. doi:10.2217/17460722.214.171.1245
Stephenson, E.L., Braude, P.B., Mason, C. 2006. Proposal for a universal minimum information convention for the reporting on the derivation of human embryonic stem cell lines. Regen Med. 1(6), 739-750. doi:10.2217/174607126.96.36.1999
Oreffo, R.O.C., Cooper, C., Mason, C., Clements, M. 2005. Mesenchymal stem cells - Lineage, plasticity and skeletal therapeutic potential. Stem Cell Reviews. 1, 169-178. ISSN:1550-8943
Mason, C., Markusen, J.F., Town, M.A., Dunnill, P., Wang, R.K. 2004. Doppler optical coherence tomography for measuring flow in engineered tissue. Biosensors and Bioelectronics. 20, 414-423. doi:10.1016/j.bios.2004.03.035
Mason, C., Markusen, J.F., Town, M.A., Dunnill, P., Wang, R.K. 2004. The potential of optical coherence tomography in the engineering of living tissue. Physics in Medicine and Biology. 7(49), 1097-1116. doi:10.1088/0031-9155/49/7/002
Page last modified on 20 sep 11 12:17